Role of Smooth Muscle Progenitor Cells in Obliterative Vascular Remodeling and PH
Role of Smooth Muscle Progenitor Cells in Obliterative Vascular Remodeling and PH
批准号:
9371373
负责人:
Zhiyu Dai
金额:
$13.26万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2019-08-31
关键词:
AddressAffectBlood PressureBlood VesselsCXCL12 geneCXCR4 geneCell ProliferationCellsCessation of lifeChronicClinicalComplexDataDiphtheria ToxinDiseaseDistalEndothelial CellsFOXM1 geneFailureGeneticHeart HypertrophyHeart failureHypertensionHypoxiaHypoxia Inducible FactorLeadLesionLungMYH11 geneMedialMediatingModelingMorbidity - disease rateMusMusclePathogenesisPatientsPharmacologyPhasePhenotypePlayPopulationProcollagen-Proline DioxygenaseProgressive DiseasePulmonary HypertensionPulmonary Vascular ResistancePulmonary artery structureReporterReportingResearchResistanceRoleSamplingSignal TransductionSmooth MuscleSmooth Muscle Actin Staining MethodSmooth Muscle MyocytesStem cellsTamoxifenTestingThickTreatment EfficacyVascular Endothelial CellVascular remodelingarterial lesionarteriolediphtheria toxin receptorforkhead proteinintima mediamortalitymouse modelnew therapeutic targetnovelprematureprimary pulmonary hypertensionprogenitorpromininpromoterreceptor expressiontreatment strategyvascular smooth muscle cell proliferation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Title: Role of Smooth Muscle Progenitor Cells in Obliterative Vascular Remodeling and PH
Abstract
Pulmonary hypertension (PH) is characterized by obliterative pulmonary vascular remodeling and progressive
elevation of pulmonary vascular resistance that leads to right heart failure and eventual death. Although great
efforts have been made with known treatment of PH, current therapies fail to reverse the disease and mortality
remains high. Better understanding of the pathogenesis of PH is warranty to identify druggable targets for PH
patients. Accumulation of smooth muscle cell (SMC) in the intima and media of pulmonary arterial lesion is the
hallmark of obliterative pulmonary vascular remodeling. However, the underlying mechanisms remain elusive.
Recently, we identified a first mouse model of PH [Tie2Cre-mediated disruption of Egln1, encoding hypoxia
inducible factor (HIF) prolyl hydroxylase 2 (PHD2), designated Egln1Tie2Cre] with progressive obliterative vascular
remodeling including vascular occlusion and plexiform-like lesion and right heart failure, which recapitulates
many features of clinical PH including idiopathic PAH. Using this model, we identified a subpopulation of smooth
muscle progenitor cells expressing CD133 (a marker of progenitor cells) and a-smooth muscle actin (a-SMA)
(CD133+ SMPCs) which were enriched at the occlusive vascular lesions as well as the plexiform-like lesions and
muscularized pulmonary arterioles. These cells expressed high levels of the proliferation-specific transcription
factor Forkhead Box M1 (FoxM1), indicating their highly proliferative potential. Genetic depletion of CD133+ cell
population inhibited chronic hypoxia-induced PH. We also observed decreased PH phenotype in another novel
mouse model with tamoxifen-inducible deletion of Foxm1 in smooth muscle cells (SMMHC-CreERT2;Foxm1f/f).
We also found that CXCL12 derived from endothelial cells (EC) regulated SMC proliferation and FOXM1
induction. Thus, my hypothesis is that pulmonary vascular ECs and SMPCs cross-talk via
CXCL12/CXCR4/FOXM1 signaling plays a fundamental role in mediating obliterative vascular remodeling and
thereby severe PH. The proposed studies will address the following Specific Aims. In Aim 1, we will define the
role of the newly identified CD133+ SMPCs in the pathogenesis of obliterative vascular remodeling and severe
PH. In Aim 2, we will address the role of FoxM1 expressed in SMPCs in oblibterative vascular remodeling and
severe PH and explore the translational potential of targeting FoxM1. In Aim 3, we will delineate the integrated
signaling responsible for obliterative pulmonary vascular remodeling in CD133+ SMPCs activated by ECs. We
expect that the proposed studies have significant translational potential by elucidating the fundamental
mechanisms of obliterative vascular remodeling and identifying druggable targets that can pharmacologically
reverse obliterative vascular remodeling for the treatment of severe PH in patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
General Capillary to Arterial Endothelial Cell Transition in Pulmonary Arterial Hypertension
-
批准号:10716738
-
项目类别:
-
资助金额:$72.17万
-
财政年份:2023
-
负责人:Zhiyu Dai
-
依托单位:
Novel alveolar mechanisms of hypoxemia in hepatopulmonary syndrome
-
批准号:10718446
-
项目类别:
-
资助金额:$76.28万
-
财政年份:2023
-
负责人:Zhiyu Dai
-
依托单位:
Fatty acid-binding proteins sustain endothelial glycolysis and arterial programming in pulmonary arterial hypertension
-
批准号:10657101
-
项目类别:
-
资助金额:$57.58万
-
财政年份:2023
-
负责人:Zhiyu Dai
-
依托单位:
Role of Endothelial SOX17 Deficiency in the Pathogenesis of Pulmonary Hypertension
-
批准号:10442975
-
项目类别:
-
资助金额:$47.98万
-
财政年份:2022
-
负责人:Zhiyu Dai
-
依托单位:
Role of Endothelial SOX17 Deficiency in the Pathogenesis of Pulmonary Hypertension
-
批准号:10594936
-
项目类别:
-
资助金额:$47.98万
-
财政年份:2022
-
负责人:Zhiyu Dai
-
依托单位:
Role of Smooth Muscle Progenitor Cells in Obliterative Vascular Remodeling and PH
-
批准号:10228636
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2019
-
负责人:Zhiyu Dai
-
依托单位:
Role of Smooth Muscle Progenitor Cells in Obliterative Vascular Remodeling and PH
-
批准号:10001625
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2019
-
负责人:Zhiyu Dai
-
依托单位:
海外基金